Even though the substance needs to be tested in more patients, it offers great possibilities for researchers looking for new metabolic answers
Retatrutide is a triple agonist, targeting the receptors of 3 hormones that can impact appetite, weight, and blood sugar levels, earning it the nicknames the triple-G and the Godzilla of weight loss jabs
Obesity: Jastreboff et al., 2023 (NEJM) Jastreboff, Kaplan, Fras, and colleagues reported a phase 2, double-blind, randomized, placebo-controlled trial in the New England Journal of Medicine in 2023 [4]
widely cited timeframes such as 28 days are unverified and should not be treated as clinical guidance
However, retatrutide is not yet FDA approved and lacks the long-term safety data that semaglutide has
Is PlexusDx Semaglutide Injection covered by insurance